Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.

ABSTRACT:

Introduction

The epidemiology of invasive Candida infections is evolving. Infections caused by non-albicans Candida spp. are increasing; however, the antifungal pipeline is more promising than ever and is enriched with repurposed drugs and agents that have new mechanisms of action. Despite progress, unmet needs in the treatment of invasive candidiasis remain, and there are still too few antifungals that can be administered orally or that have CNS penetration.

Areas covered

The authors shed light on those antifungal agents active against Candida that are in early- and late-stage clinical development. Mechanisms of action and key pharmacokinetic and pharmacodynamic properties are discussed. Insights are offered on the potential future roles of the investig

SUBMITTER: Hoenigl M 

PROVIDER: S-EPMC9339492 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature